Michael Overman

42PUBLICATIONS
259CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Predictive and prognostic markersMedical molecular engineering of nucleic acids and proteins
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (42)

|Sep 02, 2026
Overall survival of immunotherapy versus standard of care in chemorefractory microsatellite stable metastatic colorectal cancer: a propensity score matched analysis of 708 patients.

|Jul 29, 2026
COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer.

|Jul 24, 2026
Impact on survival of severe immuno-related adverse events in deficient mismatch repair/microsatellite instable-high digestive cancers treated with immunotherapy.

|Nov 18, 2025
Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants.

Giulia Maddalena, Fadl A Zeineddine, Saikat Chowdhury

|Nov 14, 2025
Impact of RAS/BRAFV600E Mutations on the Tumor Immune Microenvironment in Mismatch Repair-Deficient/Microsatellite Instability Colorectal Cancers.

Mohamed E Salem, Alberto Puccini, Elizabeth Mauer

|Jul 16, 2025
Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT.

Andrew J Pellatt, Alisha Bent, Nicholas Hornstein

Pageof 7

Frequent Collaborators

9 joint publications

Scott Kopetz

9 joint publications

Kanwal Raghav

8 joint publications

John Paul Shen

7 joint publications

N Arvind Dasari